Keyword: Charles Grassley
Think President Trump's bid to slap price tags on drug ads is all talk? Think again. In recent days, the idea has gained steam—and bipartisan backing.
After pharma suffered an unexpected loss in this year's budget deal, the industry sees an opportunity to get some relief.
Congress hasn't made progress on pricing reform, but a group of lawmakers are pushing to reduce waste in pharmaceuticals.
It didn't take long for Congress to push back at Allergan's first-of-a-kind patent deal with the Saint Regis Mohawk Tribe.
Mylan has finished a settlement with the Department of Justice for $465 million relating to EpiPen’s misclassification on Medicaid.
Mylan has agreed to meet with Sen. Chuck Grassley, who is investigating a Medicaid drug misclassification that cost taxpayers more than $1.2 billion.
Mylan agreed to pay $465M to settle a federal probe into underpaid Medicaid rebates, but that's less than half the cost to taxpayers, HHS says.
U.S. government watchdogs plan to probe the FDA's orphan drug policies after Marathon's high-profile pricing scandal.
Marathon’s Emflaza pricing remains in an unwelcome spotlight as eight more senators zero in on the company and its newly approved, $89,000 DMD med.
Even as orphan drug laws get a new round of scrutiny in Congress, a new report outlines just how much sales for the meds are expected to take off in the coming years.